Presymptomatic genetic testing for neurodegenerative diseases can help patients make effective treatment decisions, but the medical profession needs to ensure that the increasing use of the tests is done responsibly.
A new AMA policy provide guidance for physician-scientists on dual-use research issues and reinforces the message that ethical conduct in scientific research ultimately rests with the individual researcher.